Processing...
Clinical Trials for Sarcoma
Search
Search
There are 170 active trials for advanced/metastatic sarcoma.
Click on a trial to see more information.
170 trials meet filter criteria.
Sort by:
TrialFetch AI summary: For adults (≥18) with relapsed/refractory, measurable soft tissue sarcoma after ≥1 prior systemic regimen (ECOG 0–1) whose tumors are FAP-PET–positive, this study treats with IV [Ac-225]RTX-2358, a fibroblast activation protein (FAP)–targeted actinium-225 alpha-emitting radiopharmaceutical delivering high–linear energy transfer cytotoxic radiation to the tumor microenvironment, dosed every 8 weeks for 4 cycles (up to 6 if benefiting). Patients also receive the investigational FAP-targeted PET imaging agent [Cu-64]LNTH-1363S for selection/imaging and dosimetry assessments.
ClinicalTrials.gov ID: NCT07156565
TrialFetch AI summary: Eligible patients are children, adolescents, and young adults (age 1 to <24 years; >10 kg) with relapsed/refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor with measurable/evaluable disease after standard therapies and no known CNS involvement. After fludarabine/cyclophosphamide lymphodepletion, participants receive a single infusion of an autologous 1:1 cellular product combining B7-H3–targeted CAR T cells with PRAME antigen–specific T cells engineered with a dominant-negative TGF-β receptor II (dTβRII) to resist TGF-β–mediated immunosuppression.
ClinicalTrials.gov ID: NCT07172958
TrialFetch AI summary: Adults with ECOG 0–1 and locally advanced unresectable or metastatic sarcoma (≤2 prior metastatic systemic lines) or selected epithelial solid tumors (≤3 prior lines) with RECIST-measurable disease and required pretreatment biopsy/archival tissue are treated with ZL-6201 monotherapy in 21-day cycles. ZL-6201 is a first-in-human LRRC15-targeting antibody–drug conjugate delivering an internalized camptothecin-derivative (topoisomerase I inhibitor) payload via a protease-cleavable linker.
ClinicalTrials.gov ID: NCT07374848
TrialFetch AI summary: For children and adults (age 1–75) with histologically confirmed osteosarcoma that is recurrent, refractory, or progressive with new/worsening measurable or evaluable disease (including FDG-PET–avid bone metastasis not in complete remission after upfront therapy), ECOG 0–2 (or Lansky/Karnofsky ≥60), adequate organ function, and able to undergo leukapheresis (prior anthracycline-based therapy generally required). Patients receive lymphodepleting fludarabine/cyclophosphamide followed by a single infusion of autologous FH-FOLR1 ST CAR T cells targeting folate receptor alpha (FOLR1/FRα) to activate T-cell cytotoxicity against FOLR1-expressing tumor cells.
ClinicalTrials.gov ID: NCT07227571
TrialFetch AI summary: For adolescents and adults (≥30 kg; ECOG 0–2/Lansky ≥50) with histologically confirmed relapsed/refractory osteosarcoma after ≥1 prior chemotherapy regimen and RECIST-measurable/evaluable disease (including FDG-PET–avid bone-only disease). Participants receive single-agent LNTH-2403, an LRRC15-targeted lutetium-177–labeled monoclonal antibody radiotherapeutic delivering beta radiation to LRRC15-expressing tumor/stroma, dosed about every 8 weeks with imaging-based biodistribution/dosimetry.
ClinicalTrials.gov ID: NCT07357519
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors refractory to standard therapy or without proven effective options receive KIVU-107, an investigational PTK7-directed antibody-drug conjugate carrying an exatecan/topoisomerase I inhibitor payload. The study includes dose escalation followed by expansion at the recommended dose, with eligibility requiring measurable disease, ECOG 0–1, and adequate organ function.
ClinicalTrials.gov ID: NCT07229313
TrialFetch AI summary: Open-label dose-escalation study of oral KST-6051, an investigational pan-KRAS inhibitor targeting both active and inactive KRAS conformations, in adults with locally advanced unresectable or metastatic KRAS-mutant solid tumors including NSCLC, pancreatic, colorectal, and other cancers. Patients must have progressed after or been intolerant of standard therapy, have ECOG 0-1 and measurable disease, with no prior/current RAS/KRAS inhibitor therapy or CNS metastases.
ClinicalTrials.gov ID: NCT07458347
TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors that have progressed on, or are unsuitable or intolerant of, standard therapy receive once-daily oral SHY-ONC6. SHY-ONC6 is a small-molecule proteasome inhibitor targeting selected AAA+ ATPases in the 19S regulatory particle to disrupt ubiquitinated protein processing and promote apoptosis.
ClinicalTrials.gov ID: NCT07705334
TrialFetch AI summary: Adults with previously treated metastatic pancreatic ductal adenocarcinoma, NSCLC, or colorectal cancer harboring KRAS G12C/D/V/A/S or G13D mutations, measurable disease, and ECOG 0–1 are eligible. Participants receive oral once-daily BLU-924 (SAR449336), an investigational pan-KRAS small-molecule inhibitor, as monotherapy.
ClinicalTrials.gov ID: NCT07629960
TrialFetch AI summary: Children and young adults aged 2–39 years with measurable, unresectable recurrent or refractory Wilms tumor or desmoplastic small round cell tumor receive IV trastuzumab deruxtecan every 21 days. Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate that delivers a topoisomerase I inhibitor payload to HER2-expressing tumor cells.
ClinicalTrials.gov ID: NCT04616560